VentriPoint Diagnostics Ltd. (CVE:VPT) Director Robert Hodgkinson Acquires 75,000 Shares of Stock

VentriPoint Diagnostics Ltd. (CVE:VPTGet Free Report) Director Robert Hodgkinson purchased 75,000 shares of the business’s stock in a transaction dated Monday, April 22nd. The shares were purchased at an average cost of C$0.21 per share, with a total value of C$15,900.00.

Robert Hodgkinson also recently made the following trade(s):

  • On Thursday, April 18th, Robert Hodgkinson acquired 36,500 shares of VentriPoint Diagnostics stock. The stock was acquired at an average cost of C$0.21 per share, for a total transaction of C$7,774.50.

VentriPoint Diagnostics Stock Performance

Shares of VentriPoint Diagnostics stock opened at C$0.21 on Tuesday. The company’s 50 day moving average price is C$0.25 and its two-hundred day moving average price is C$0.24. The firm has a market capitalization of C$32.93 million, a P/E ratio of -7.00 and a beta of 0.39. VentriPoint Diagnostics Ltd. has a fifty-two week low of C$0.12 and a fifty-two week high of C$0.36. The company has a debt-to-equity ratio of 32.61, a current ratio of 2.06 and a quick ratio of 6.67.

About VentriPoint Diagnostics

(Get Free Report)

Ventripoint Diagnostics Ltd., a medical device company, engages in the development and commercialization of diagnostic tools that monitor patients with heart disease worldwide. The company offers Ventripoint Medical System (VMS), a medical imaging system that is used to generate three-dimensional models with critical volume and functional measurements of a patient's heart chambers; VMS+ software for use in creating three-dimensional model that generates accurate heart volumetric measurements.

See Also

Receive News & Ratings for VentriPoint Diagnostics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for VentriPoint Diagnostics and related companies with's FREE daily email newsletter.